Thank you for your business, support and partnership in 2020!  Medicilon appreciates working with you and

Jan 29th, 2021 – CDE announced that the innovative drug, 3D011-08 from 3D Medicines, was approved

Jan.27, 2021 – Xuanzhu Biotech announced that their XZP-5610, a new treatment for NASH (non-alcoholic steatohepatitis),

Recently, Shanghai Medicilon was awarded the title of “Excellent Expert Workstation” by the Shanghai Academician and

You may say that the Coronavirus Pandemic will define 2020. You may say that 2020 has

Inflammatory immune diseases have gained much attention as the incidence has grown bigger each year. The

Dec.20, 2020, Hebei—The 13th China Pharmaceutical Strategy Conference 2020 was held successfully. The conference presented the

Medicilon has constructed the GMP Drug Products Pilot Plant to meet the rising needs for innovative